||EPS - Basic
||Market Cap (m)
|Pharmaceuticals & Biotechnology
Immupharma Share Discussion Threads
Showing 6926 to 6947 of 6950 messages
|So will imm meet the full patient target by year end? Getting tight now.|
|No worries. We are due an RNS of course - both notifying us of the new patent as well as the all important status of patient recruitment for the Phase III trial.|
|Sorry, let me put my specs back on. Misread the date. I'll delete the post.
(Saw the turn up in share price and read the last RNS thinking it was today's. )|
|Today's RNS reads like very good news, though not about lupus. Would SK kindly care to explain its import to shareholders?|
Found a list of sites while searching not updated since 7 november but says 30 recruiting,|
|Sylviane Muller recently presented at the Meeting of TRANSAUTOPHAGY in Warsaw. The link below is to the programme for the conference and the full abstract will be found under oral presentations (no. 9).
The title of her presentation is " Lysosomal HSPA8, a key element in the mechanism of action of therapeutic P140 peptide/Lupuzor" and shows that the mechanism of action for Lupuzor has been further defined. Essentially, it appears that Lupuzor inhibits heat shock protein HSPA8 which is associated with a number of diseases as well as the aging process.
The abstract details how HSPA8 plays an important role in chaperone-mediated autophagy (CMA) which is one of the 3 main types of autophagy and is associated with lupus. The final sentence from the abstract:-
" All these targeted effects concur to downregulate the excessive CMA activity that occurs in lupus and to “reconfigure8221; the immune system in an otherwise deleterious autoimmune context"
|A binary gamble. BUT: I do like charts, do like the story here c/o SK and others; and since 2017 seems to be the Year of Make or Break, I have decided to re-enter with a small amount on the basis that in the absence of BAD NEWS this is likely to go up sharply as we approach results. In the not unlikely event that it doubles, I will then sell half.
|Courtesy of fingers' excellent charting thread [Epic FXD]|
|Read the Edison note they quote that Anifolumab from AstraZeneca as the most immediate competitor.Either they have not done there research or don't expect Lupuzor to succeed but very strange no mention,any thoughts.|
|If/When Lupuzor gets through Phase III unscathed and to market she may well find herself awarded a special Qazwsxedc69 medal (for services to my bank account).|
|Congratulations to Immupharma co founder and Lupuzor inventor Prof. Sylviane Muller who has received yet another award for her work on Lupuzor. She has received the Leon Velluz Award from the French Académie des Sciences - one of the oldest scientific academies in the World.
Below are some of the awards already received in recognition of her discovery of Lupuzor and work in the field of autophagy:-
award of excellence from the Endocrine Society and Pfizer
the Apollo-B award from Roche
CNRS Silver Medal
CNRS Gold Medal
Chevalier de l’Ordre de la Légion d’Honneur (2010).|
|In principle it shouldn't make any difference, but it is a key milestone and marks not only a 1st for IMM (hitting a deadline), but means the results are likely to be on-time, rather than delayed through slow recruitment and importantly means no (to date) adverse events.
The next big reporting event would be the results, and I doubt we will be trading anywhere near this price as we get closer to those (even though we won't know if they are positive or not until they report)
Edit: If we had outlicensed getting to full recruitment would be a milestone trigger.|
|Not doubting you Waterloo, just a lack of knowledge on my part - does timely full recruitment typically have a specific positive impact on share price? I don't necessarily see why it should? Thanks.|
|Looking for a re rating here if they manage to get full recruitment complete by year end. Could/should see it touch the highs in the 70's/80's IMO|
|Thanks for clarification on the target price although for those of us who have been here a while I don't think it changes our view on the prospects. I did top up again but that's about my limit now, definitely top heavy IMM but I can't see the same potential value anywhere else. I have my relatively safe investments and this as my risky punt.|
|SK - thanks for the response (1503).|
Well certainly Vadim Alexandre didn't correct the interviewer when he was asked about the 137 target so both perhaps at fault. Having said that, it's the first time I've seen Vadim Alexandre interviewed and thought he was very impressive. A pleasant contrast perhaps to Dr. Mike Mitchell's (Panumure) rather quiet and low key approach.|
|Interviewee I think, but yes.
|Northland have not cut their price target, see:
Target price remains 171p.|
I can confirm that Northland's target price hasn't been cut and remains unchanged at 171p - the interviewer made a mistake!!|
|Looks like Northland have cut the Buy target from 171p to 137p.
Bit academic really. Perhaps 171p was a bit embarrassing since it has stuck around 40p for a number of months.
I wonder if any UK sites will be opened, I half expect an announcement in mid-December to say recruitment has been completed without any further locations being announced.|